Skip to main content

Table 2 Comparison of baseline kidney histopathology data and prior immunosuppressive treatment

From: Comparison of clinical features and outcomes between patients with early and delayed lupus nephritis

Variables Total (n = 171) Patients with early lupus nephritis (n = 106) Patients with delayed lupus nephritis (n = 65) p-value
Kidney histopathology data
Lupus nephritis class
  Class I 3 (1.8) 0 (0.0) 3 (4.6) 0.053
  Class IIa 7 (4.1) 4 (3.8) 3 (4.6) 0.999
  Class IIIa 57 (33.3) 35 (33.0) 22 (33.8) 0.801
  Class IVa 84 (49.1) 53 (50.0) 31 (47.7) 0.770
  Class Va 42 (24.6) 29 (27.4) 13 (20.0) 0.279
  Class VI 0 (0.0) 0 (0.0) 0 (0.0) 0.999
Activity/Chronicity
  Activity index 7.0 (2.0–11.8) 7.0 (2.0–11.0) 8.0 (3.0–12.0) 0.323
Chronicity index, n (%)     0.007
 0–1 104 (60.8) 71 (67.0) 33 (50.8)  
 2–3 51 (29.8) 30 (28.3) 21 (32.3)  
 4–5 13 (7.6) 4 (3.8) 9 (13.8)  
 6 3 (1.8) 1 (0.9) 2 (3.1)  
Prior immunosuppressive agent use
  Glucocorticoids 64 (37.4) 0 (0.0) 64 (98.5) < 0.001
  Cyclophosphamide 1 (0.6) 0 (0.0) 1 (1.5) 0.380
  Mycophenolate mofetil 2 (1.2) 0 (0.0) 2 (3.1) 0.143
  Tacrolimus 1 (0.6) 0 (0.0) 1 (1.5) 0.380
  Cyclosporine 2 (1.2) 0 (0.0) 2 (3.1) 0.143
  Azathioprine 10 (5.8) 0 (0.0) 10 (15.4) < 0.001
  Methotrexate 3 (1.8) 0 (0.0) 3 (4.6) 0.053
  Hydroxychloroquine 44 (25.7) 0 (0.0) 44 (67.7) < 0.001
  1. Values are expressed as median (interquartile range) or n (%)
  2. aMixed lupus nephritis cases were counted for each respective class